Syndax Pharmaceuticals Reports Q4 Earnings and 2026 Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy SNDX?
Source: seekingalpha
- Earnings Report: Syndax Pharmaceuticals reported a Q4 GAAP EPS of -$0.78, missing expectations by $0.23, indicating challenges in profitability that may affect investor confidence.
- Revenue Surge: The company achieved Q4 revenue of $68.7 million, a staggering 794.5% increase year-over-year, surpassing estimates by $3.95 million, reflecting significant market acceptance of its products and laying a foundation for future growth.
- Expense Forecast: Syndax anticipates total research and development plus selling, general, and administrative expenses to reach approximately $400 million in 2026, excluding an estimated $50 million in non-cash stock compensation, which could exert pressure on the company's cash flow.
- Market Outlook: Despite profitability challenges, Syndax's early market performance signals continued growth potential, particularly with product launches in 2026, which may attract increased investor interest.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNDX
Wall Street analysts forecast SNDX stock price to rise
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.000
Low
27.00
Averages
39.11
High
56.00
Current: 24.000
Low
27.00
Averages
39.11
High
56.00
About SNDX
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sphera Increases Stake in Syndax Pharmaceuticals
- Share Acquisition: On February 17, 2026, Sphera Funds Management Ltd. disclosed the purchase of 374,847 shares of Syndax Pharmaceuticals, representing an estimated $6.54 million trade, indicating strong confidence in the company.
- Increased Ownership: This acquisition raised Syndax's stake to about 3% of Sphera's 13F reportable assets, reflecting its growing significance within the investment portfolio.
- Revenue Growth: Syndax's total revenue reached $172.4 million in 2025, a substantial increase driven by the successful launches of Revuforj and Niktimvo, showcasing the company's transition from clinical to commercial phases.
- Stock Performance: As of last Friday, Syndax's shares were priced at $23.99, up 83% over the past year, significantly outperforming the S&P 500's roughly 20% gain, indicating optimistic market expectations for its future growth.
See More
Sphera Funds Increases Stake in Syndax Pharmaceuticals
- Increased Holdings: Sphera Funds added 374,847 shares of Syndax Pharmaceuticals in Q4 2026, raising its total holdings to 762,563 shares valued at $16.02 million, reflecting strong confidence in the company's prospects.
- Quarterly Performance: The position value rose by $10.06 million in the fourth quarter, driven by both trading activities and stock price movements, indicating optimistic market expectations for future growth.
- Revenue Growth: Syndax's Revuforj drug generated $44.2 million in net revenue in Q4, a 38% sequential increase, contributing to a full-year revenue of $124.8 million, showcasing robust market performance.
- Commercialization Progress: With two approved therapies, Syndax's total revenue reached $172.4 million in 2025, a significant increase from $23.7 million the previous year, marking a successful transition from clinical trials to a viable operating business.
See More
Syndax Pharmaceuticals Grants Stock Options to New Employees
- Stock Option Grant: On March 1, 2026, Syndax Pharmaceuticals granted inducement awards for up to 81,600 shares of common stock to three new employees, aimed at attracting and retaining key talent, thereby enhancing the company's innovative capabilities and market competitiveness.
- Vesting Schedule: The stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date, and the remaining shares vesting monthly over the next 36 months, ensuring continued employee contributions during their service.
- Innovative Drug Pipeline: Syndax's pipeline includes FDA-approved drugs Revuforj® and Niktimvo™, indicating the company's ongoing investment and research capabilities in cancer treatment, aimed at meeting market demands for new therapies.
- Clinical Trial Advancement: The company is conducting several clinical trials to unlock the full potential of its pipeline, further driving innovation in cancer treatment and improving patient outcomes and quality of life.
See More
Syndax (SNDX) Q4 2025 Earnings Call Transcript
See More
Syndax Pharmaceuticals Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: Syndax Pharmaceuticals reported total revenue of $172.4 million for 2025, with Revuforj net revenue reaching $124.8 million, reflecting a 38% year-over-year increase, indicating strong market demand and product uptake that is expected to drive continued growth.
- Outstanding Niktimvo Performance: Niktimvo generated $152 million in net revenue in the first 11 months of 2025, surpassing the benchmark set by Sanofi's REZUROCK, demonstrating Syndax's competitive edge and rapid market share expansion in the new drug sector.
- Sustained R&D Investment: With $394 million in cash and equivalents at the end of 2025, the company is well-positioned to meet its funding needs for future R&D and market expansion, supporting its strategic goal of targeting a total addressable market exceeding $10 billion.
- Clinical Trial Progress: Enrollment for the MAXPIRe Phase II trial has been completed, with topline data expected in Q4 2026, which will provide critical data support for the company's further development in specific disease areas.
See More
Syndax Pharma Reports Q4 Loss and Revenue Surge
- Financial Performance: Syndax Pharma reported a Q4 net loss of $68.01 million, or $0.78 per share, which is an improvement from last year's loss of $94.17 million and $1.10 per share, indicating progress in loss control.
- Revenue Surge: The company's Q4 revenue soared to $68.73 million, a staggering 794.9% increase from $7.68 million last year, reflecting strong product sales and market demand recovery, potentially laying the groundwork for future profitability.
- Improved Profitability: Although still in the red, the reduced loss compared to last year suggests that Syndax Pharma has made strides in cost management and operational efficiency, which may attract more investor interest in its growth potential.
- Market Outlook: With rapid revenue growth and shrinking losses, Syndax Pharma's competitive position in the biopharmaceutical sector is expected to strengthen, particularly in new product launches and market expansion, potentially leading to greater market share.
See More
Sphera Increases Stake in Syndax Pharmaceuticals
- Share Acquisition: On February 17, 2026, Sphera Funds Management Ltd. disclosed the purchase of 374,847 shares of Syndax Pharmaceuticals, representing an estimated $6.54 million trade, indicating strong confidence in the company.
- Increased Ownership: This acquisition raised Syndax's stake to about 3% of Sphera's 13F reportable assets, reflecting its growing significance within the investment portfolio.
- Revenue Growth: Syndax's total revenue reached $172.4 million in 2025, a substantial increase driven by the successful launches of Revuforj and Niktimvo, showcasing the company's transition from clinical to commercial phases.
- Stock Performance: As of last Friday, Syndax's shares were priced at $23.99, up 83% over the past year, significantly outperforming the S&P 500's roughly 20% gain, indicating optimistic market expectations for its future growth.
See More
Sphera Funds Increases Stake in Syndax Pharmaceuticals
- Increased Holdings: Sphera Funds added 374,847 shares of Syndax Pharmaceuticals in Q4 2026, raising its total holdings to 762,563 shares valued at $16.02 million, reflecting strong confidence in the company's prospects.
- Quarterly Performance: The position value rose by $10.06 million in the fourth quarter, driven by both trading activities and stock price movements, indicating optimistic market expectations for future growth.
- Revenue Growth: Syndax's Revuforj drug generated $44.2 million in net revenue in Q4, a 38% sequential increase, contributing to a full-year revenue of $124.8 million, showcasing robust market performance.
- Commercialization Progress: With two approved therapies, Syndax's total revenue reached $172.4 million in 2025, a significant increase from $23.7 million the previous year, marking a successful transition from clinical trials to a viable operating business.
See More
Syndax Pharmaceuticals Grants Stock Options to New Employees
- Stock Option Grant: On March 1, 2026, Syndax Pharmaceuticals granted inducement awards for up to 81,600 shares of common stock to three new employees, aimed at attracting and retaining key talent, thereby enhancing the company's innovative capabilities and market competitiveness.
- Vesting Schedule: The stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date, and the remaining shares vesting monthly over the next 36 months, ensuring continued employee contributions during their service.
- Innovative Drug Pipeline: Syndax's pipeline includes FDA-approved drugs Revuforj® and Niktimvo™, indicating the company's ongoing investment and research capabilities in cancer treatment, aimed at meeting market demands for new therapies.
- Clinical Trial Advancement: The company is conducting several clinical trials to unlock the full potential of its pipeline, further driving innovation in cancer treatment and improving patient outcomes and quality of life.
See More
Syndax (SNDX) Q4 2025 Earnings Call Transcript
See More
Syndax Pharmaceuticals Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: Syndax Pharmaceuticals reported total revenue of $172.4 million for 2025, with Revuforj net revenue reaching $124.8 million, reflecting a 38% year-over-year increase, indicating strong market demand and product uptake that is expected to drive continued growth.
- Outstanding Niktimvo Performance: Niktimvo generated $152 million in net revenue in the first 11 months of 2025, surpassing the benchmark set by Sanofi's REZUROCK, demonstrating Syndax's competitive edge and rapid market share expansion in the new drug sector.
- Sustained R&D Investment: With $394 million in cash and equivalents at the end of 2025, the company is well-positioned to meet its funding needs for future R&D and market expansion, supporting its strategic goal of targeting a total addressable market exceeding $10 billion.
- Clinical Trial Progress: Enrollment for the MAXPIRe Phase II trial has been completed, with topline data expected in Q4 2026, which will provide critical data support for the company's further development in specific disease areas.
See More
Syndax Pharma Reports Q4 Loss and Revenue Surge
- Financial Performance: Syndax Pharma reported a Q4 net loss of $68.01 million, or $0.78 per share, which is an improvement from last year's loss of $94.17 million and $1.10 per share, indicating progress in loss control.
- Revenue Surge: The company's Q4 revenue soared to $68.73 million, a staggering 794.9% increase from $7.68 million last year, reflecting strong product sales and market demand recovery, potentially laying the groundwork for future profitability.
- Improved Profitability: Although still in the red, the reduced loss compared to last year suggests that Syndax Pharma has made strides in cost management and operational efficiency, which may attract more investor interest in its growth potential.
- Market Outlook: With rapid revenue growth and shrinking losses, Syndax Pharma's competitive position in the biopharmaceutical sector is expected to strengthen, particularly in new product launches and market expansion, potentially leading to greater market share.
See More
